[89Zr]Zr-Df-Crefmirlimab

NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc (“ImaginAb”), a market leading global biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies. Under the terms of the agreement, ImaginAb will supply clinical doses of its market leading CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in a study implemented as part of BriaCell’s ongoing Phase I/IIa study with Incyte in metastatic or locally recurrent breast cancer patients. Specifically, ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology. No other terms are disclosed. The CD8 ImmunoPET technology allows whole body visualization of increased CD8 T cells, especially those infiltrating and attacking tumors. BriaCell will use the technology to provide a readout of both safety and efficacy of its novel cancer immunotherapy. Dr. Bill Williams, President and CEO of BriaCell, commented, “ImaginAb’s cutting edge CD8 ImmunoPET technology has been used by leading cancer drug developers to more accurately analyze tumors and immune responses to cancer treatments. We look forward to working with the team of experts at ImaginAb to evaluate the safety and efficacy of BriaCell’s immunotherapy treatments in patients with advanced breast cancer.” Ian Wilson, CEO of ImaginAb, stated, “We are delighted to welcome BriaCell as a new clinical partner, especially as it is the first time 89Zr-Df-Crefmirlimab will be used to image the response of breast cancer to their novel targeted immunotherapy treatment. We are excited about the benefits 89Zr-Df-Crefmirlimab can potentially bring to patients and how it could help BriaCell accelerate the development of its novel immunotherapy treatments. “ImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives. Our CD8 ImmunoPET technology enables quicker identification of drug efficacy, potentially reducing the length of trials and allowing new therapies to advance to market quicker, and may remove the need for repeat, painful biopsies, all of which could ultimately transform patient care.” About BriaCell Therapeutics Corp. BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at . About ImaginAb ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets, including the 89Zr CD8 ImmunoPET targeting CD8 T cells. ImaginAb’s products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb’s pipeline and technology, visit . Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at and on EDGAR at . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com Media Relations:Jules AbrahamDirector of Public RelationsCORE IR917-885-7378julesa@coreir.com Investor Relations Contact:CORE IRinvestors@briacell.com ImaginAbIan WilsonCEO310-645-1211info@imaginab.com

June 30, 2021 11:00 UTC Study sponsored by ImaginAb supports hypothesis that CD8+ T cells are present throughout the skeletal muscle system in inclusion body myositis Proprietary ImmunoPET technology developed by ImaginAb provides a more comprehensive view of T cell infiltration than offered by muscle biopsies NEWTON, Mass.--(BUSINESS WIRE)-- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, and ImaginAb, a market leading global provider in immune-oncology imaging agents, today shared initial results of a study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis (IBM). IBM is an autoimmune disease in which cytotoxic CD8+ T cells chronically attack muscle cells, leading to progressive weakness and severe disability. This news announcement follows the signing of a new non-exclusive license agreement in February 2021 for ImaginAb to supply Abcuro with its market leading CD8 ImmunoPET agent. The proprietary first in class ImmunoPET imaging agent allows non-invasive, whole-body imaging CD8+ T cells using positron emission tomography (PET). The technology, initially designed to visualize these cells in cancer patients, can now provide a non-invasive assessment of the extent of infiltration of CD8+ T cells in skeletal muscle in IBM patients. “The ability to comprehensively identify infiltration of CD8+ T cells in skeletal muscle represents a breakthrough in our understanding of IBM pathogenesis and supports development of novel therapeutics,” said Steven A. Greenberg, M.D., co-founder of Abcuro and Chief Scientific Advisor. “Abcuro intends to use this imaging strategy as it advances ABC008, an anti-KLRG1 antibody capable of selectively depleting a subpopulation of highly-cytotoxic CD8+ T cells present in muscle tissue of IBM patients, through a first-in-human clinical trial for IBM.” Ron Korn, M.D., Ph.D., Chief Medical Imaging Officer at ImaginAB stated, “Our proprietary antibody-fragment imaging technology binds to and illuminates the specific immune cell type that is central to the etiology of IBM. The ability to image the entire landscape of skeletal muscle in IBM patients enrolled in their trials enables Abcuro to comprehensively assess the presence of CD8+ T cells prior to and following dosing of ABC008, which seeks to address the underlying biological driver of IBM.” The imaging study was led by Colin Quinn, M.D., Assistant Professor of Clinical Neurology and Director of Neuromuscular Clinical Trials at the University of Pennsylvania. “The understanding of IBM as a T cell-driven autoimmune disease has enabled use of PET imaging to provide a highly specific, whole-body view of CD8+ T cells, the presence of which is a potentially distinguishing feature in affected muscle tissue,” said Dr. Quinn. About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of T and NK cells that express KLRG1 (killer cell lectin like receptor G1). In certain autoimmune diseases, KLRG1-expressing T cells are a source of chronic tissue damage. In oncology, tumor cells that express E- or N- cadherin inhibit anti-tumor activity of T and NK cells via their KLRG1 receptor, which is an immune checkpoint inhibitory receptor. KLRG1 was identified as a compelling target with relevance to disease biology through Abcuro’s powerful use of patient clinical data and patient tissue transcriptome analyses derived from discrete, pathological immune cell subpopulations. For more information, visit . About ImaginAb ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets including the 89Zr CD8 ImmunoPET targeting CD8 T cells. ImaginAb’s products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine ventures Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb’s pipeline and technology, visit . About CD8 ImmunoPET The 89Zr CD8 ImmunoPET agent ([89Zr]-Df-Crefmirlimab) is a [89Zr]-labeled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes. View source version on businesswire.com: Contacts Christine Quern CBQ Communications cq@christinequern.com 617.650.8497 Source: Abcuro, Inc. View this news release online at: